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Heartrateturbulence(HRT)isthebaroreﬂex-mediatedshort-termoscillationofcardiaccycle
lengths after spontaneous ventricular premature complexes. HRT is composed of a brief
heart rate acceleration followed by a gradual heart rate deceleration. In high risk patients
after myocardial infarction (MI) HRT is blunted or diminished. Since its ﬁrst description in
1999 HRT emerged as one of the most potent risk factors after MI. Predictive power of
HRT has been studied in more than 10,000 post-infarction patients.This review is intended
to provide an overview of HRT as risk-predictor after MI.
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INTRODUCTION
Despitesigniﬁcantadvancesininterventionalandmedicaltherapy
late mortality after myocardial infarction (MI) is still high. A sub-
stantial number of these late deaths occur suddenly, potentially
preventable by an implantable cardioverter-deﬁbrillator (ICD).
Randomized multicenter trials have shown that mortality can be
reduced in post-infarction patients at high risk for death by 20–
54% (Moss et al., 1996, 2002; Buxton et al., 1999; Bristow et al.,
2004; Bardy et al., 2005). Current guidelines recommend ICD
implantationinpatientscharacterizedbyacompromisedleftven-
tricular ejection fraction (LVEF 30–35%) which is considered to
be the gold standard in risk prediction (Gregoratos et al., 2002;
Zipes et al., 2006).
However, clinical studies have consistently shown that the cri-
terion of a reduced LVEF is neither sensitive nor speciﬁc. It lacks
of sensitivity as approximately 2/3 of deaths in post-infarction
patients occur in patients with LVEF >35% who are not covered
by the criterion of reduced LVEF (Myerburg et al., 1997, 1998;
Huikuri et al.,2001;Buxton,2003). It also lacks of speciﬁcity as 11
ICDshavetobeimplantedtosaveonelife(Cammetal.,2007).The
majority of ICD recipients will never receive an adequate shock.
Therefore, development of additional risk stratiﬁcation strategies
is urgently needed.
Twelve years ago, an electrocardiographic phenomenon later
on termed “heart rate turbulence (HRT)” has been described
(Schmidt et al., 1999). At that time, it has been ﬁrstly recog-
nized that in healthy persons spontaneous ventricular premature
complexes(VPC)arefollowedbyacharacteristicshort-termoscil-
lationofheartrate.Theoscillationiscomposedofabriefheartrate
acceleration followed by a gradual heart rate deceleration before
returning to baseline. As post-ectopic changes of cycle lengths are
in the range of milliseconds and masked by heart rate variability
of other origin it can only be visualized by signal averaging.
Very early it became clear that post-infarction patients
at increased risk for adverse events showed different post-
extrasystolicpatternsof heartrate.Inhighriskpatientsthetypical
HRT response is blunted or entirely missing. Within the last
decade, HRT emerged as one of the most potent ECG based
risk predictors. Several large-scale studies have demonstrated its
strong prognostic power in post-infarction patients. This review
is intended to provide a review of HRT as risk-predictor in
post-infarction patients.
MEASUREMENT OF HEART RATE TURBULENCE
Heart rate turbulence is obtained from standard 24-h Holter
recordings with a minimum temporal resolution of 128Hz which
allow for accurate determinations of RR intervals and beat classi-
ﬁcations. In contrast to other techniques such as T-wave alternans
no speciﬁc electrodes or other equipments are needed. The tech-
nical assessment of HRT has been described in details elsewhere
(Bauer et al., 2008). Brieﬂy, the RR intervals surrounding spon-
taneous VPCs are averaged in order to obtain a so-called local
tachogram demasking the average pattern of sinus RR intervals
surrounding VPCs (Figure 1). VPCs used for HRT computation
needtofulﬁllcertaincriteriawithrespecttoprematurityandcom-
pensatory pause. Details regarding these ﬁlter criteria have been
described elsewhere (Bauer et al., 2008).
The two phases of HRT are quantiﬁed by the two parameters
turbulence onset (TO) and turbulence slope (TS).
Turbulence onset is calculated as follows:
TO =
(RR1 + RR2) − (RR−2 + RR−1)
(RR−2 + RR−1)
× 100[%]
whereas RR−2 and RR−1 are the two RR intervals immedi-
ately before the VPC coupling interval. RR1 and RR2 are the
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FIGURE 1 |Assessment of heart rate turbulence (HRT) from 24-h Holter
recordings: (A) high variability in single “local tachograms” surrounding
randomly selected ventricular premature complexes (VPCs); (B) high
circadian variability in single local tachograms observed over 24h;
although typical HRT response can be suggested from this graph; (C)
smooth HRT pattern (red curve) after signal averaging of single
tachograms (gray curves). Quantiﬁcation of HRT by turbulence onset and
turbulence slope (see text for explanation).
two RR intervals which immediately follow the compensatory
pause. TS is deﬁned as the maximum positive regression slope
assessed over any ﬁve consecutive sinus RR intervals within
the ﬁrst 15 RR intervals following the VPC. Hence, in nor-
mal subjects, the initial acceleration of sinus rate after the
VPC is characterized by negative TO and the following heart
rate deceleration is characterized by positive TS. TO <0% and
TS >2.5ms/RR interval are considered normal (Bauer et al.,
2008).
For use of risk stratiﬁcation in different patient populations,
HRT is usually divided into three categories: (1) HRT cate-
g o r y0i sd e ﬁ n e da sn o r m a lT Oand normal TS, (2) HRT cat-
egory 1 means that either TO or TS are abnormal, and (3)
HRT category 2 is characterized by both abnormal TO and
TS. If no sufﬁcient VPC tachograms are recorded and patients
are otherwise in sinus rhythm, HRT is classiﬁed as category
0 since those patients were shown to have equally good prog-
nosis as patients with normal HRT (Barthel et al., 2003). As
this was only shown for post-infarction patients, this approach
might not be valid if other pathologies (e.g., heart failure) are
considered.
The HRT software is commercially available on GE and
Getemed Holter systems. However, as the algorithms have been
published in detail (www.h-r-t.com) HRT can also be obtained
from the series of RR intervals by a custom-made software.
PHYSIOLOGY OF HEART RATE TURBULENCE
When the ﬁrst clinical studies of HRT in risk prediction have been
published the exact physiological mechanisms behind HRT were
largely unknown (Schmidt et al.,1999;Bauer and Schmidt,2007).
The (patho)physiological mechanisms behind HRT are complex
and involve both branches of the autonomic nervous system. In
their work, Wichterle et al. (2006) provide an excellent review of
HRT physiology. The VPC induces a transient drop of arterial
blood pressure which leads to an activation of the barorecep-
tors. Vagal activity is abruptly withdrawn resulting in an almost
Frontiers in Physiology | Clinical andTranslational Physiology December 2011 | Volume 2 | Article 99 | 2Zuern et al. Risk prediction by heart rate turbulence
immediateshorteningofRRintervalcyclelengths(asmeasuredby
TO). However,also the sympathetic system reacts (Segerson et al.,
2007). Increased sympathetic activity results in a gradual increase
of vascular resistance and systolic arterial blood pressure. As con-
sequence,vagal activity reestablishes and cycle lengths prolong (as
measuredbyTS).Importantly,HRTrequiresanintactinterplayof
both,vagal and sympathetic systems.Absence of normal HRT can
be caused by an alteration in one of the systems (Wichterle et al.,
2006).
HRT STUDY POPULATIONS
Evidence of HRT as risk-predictor in post-infarction patients is
based on ﬁve retrospective and ﬁve prospective studies includ-
ing a total of more than 10,000 patients. Study characteristics are
summarized in Tables 1 and 2.
Heart rate turbulence was originally developed in a small
dataset comprising of 100 patients suffering from coronary artery
disease and subsequently validated in a blinded fashion in the
cohorts of the MPIP study (n =577) and the placebo arm of the
EMIATstudy(n =614;Schmidtetal.,1999).Twoyearslater,Ghu-
ran et al. (2002) tested the predictive power of HRT in the dataset
of the ATRAMI study (n =1,212) which was originally designed
to assess the prognostic power of baroreﬂex sensitivity. Another
3yearslater,predictivepowerof HRTwasalsotestedinthedataset
of the CAST study (n =744; Hallstrom et al.,2005). The FINGER
study combined a Finish and German post-infarction population
(Bartheletal.,2003;Huikurietal.,2003)tospeciﬁcallyaddressthe
question whether HRT predicts sudden death (Makikallio et al.,
2005).
In 2003, the results of the ﬁrst prospective study ISAR-HRT
(n =1,455) were published which was designed to validate the
prognostic value of HRT in a large cohort of post-infarction
patients receiving contemporary treatment (Barthel et al., 2003).
The REFINE study (n =322) published 2007 was designed to
assess the predictive value of a combination of several risk
predictors including HRT as well as the time of their assess-
ment after acute MI (Exner et al., 2007). In 2009, the results
of the largest prospective HRT study were published. ISAR-
RISK tested the prognostic value of a combination of HRT and
deceleration capacity (Bauer et al., 2006a) in post-infarction
patients with preserved LVEF (Bauer et al., 2009a). Decelera-
tion capacity is an integral measure of all deceleration related
modulations of heart rate observed over 24h and thus, most
presumably, a measure of tonic vagal activity. The CARISMA
study (n =312) deserves special attention as loop recorders
have been implanted in all patients to speciﬁcally address the
endpoint of severe arrhythmic events (Huikuri et al., 2009).
Very recently, the results of ISAR-SWEET have been published
Table 1 | Retrospective studies (or sub-studies) investigating heart rate turbulence as a post-infarction risk-predictor.
MPIP
(Schmidt
et al., 1999)
EMIAT
(Schmidt
et al., 1999)
ATRAMI
(Ghuran et al.,
2002)
CAST
(Hallstrom
et al., 2005)
FINGER
(Makikallio
et al., 2005)
Number of patients 577 614 1,212 744 2,130
Year of publication of
original study
1983 1997 1998 1991 2003
Inclusion criteria* MI ≤4weeks,
age ≤70years
MI ≤4weeks, age
≤75years, LVEF ≤40%
MI ≤4weeks,
age ≤80years
MI ≥6 VPC/h MI ≤4weeks, age
≤75years
Follow-up (months) 22 21 20 55 33
Endpoint Mortality Mortality Cardiac mortality† Mortality Sudden death
Endpoints reached (%) 13 14 4 29‡ 2
Time of HRT
assessment after MI
2nd week 2nd to 3rd week 2nd to 4th week 10weeks 2nd week
Treatment of acute MI None 60% Lysis 63% Lysis 28% Lysis 70% PCI, 14% lysis
Mean LVEF (%) 45 30 49 37 Not speciﬁed
Betablockers (%) 55 32 20 30 94
UNIVARIATEANALYSIS
HRT category 2 5.0 (2.8–8.8) 4.4 (2.6–7 .5) 6.9 (3.1–15.5) Not speciﬁed 4.6 (2.6–8.1)||
LVEF ≤30% 4.0 (2.5–6.4) 2.2 (1.4–3.5) 4.7 (2.6–8.3) Not speciﬁed 4.5 (2.5–8.0)#
MULTIVARIATEANALYSIS
HRT category 2 3.2 (1.7–6.0) 3.2 (1.8–5.6) 4.1 (1.7–9.8) 20.4 (10.2–30.6)** 2.9 (1.6–5.5)
LVEF ≤30% 2.9 (1.8–4.9) 1.7 (1.1–2.7) 3.5 (1.8–7 .1) Not speciﬁed Not speciﬁed
*Sinus rhythm was inclusion criterion in all studies.
†Cardiac Mortality included fatal and non-fatal cardiac arrest.
‡Cumulative mortality rate only presented for total study population of CAST after 5years.
||Relative risks presented for turbulence slope ≤2.5ms/RR interval.
#LVEF was dichotomized at 35%.
**Log ofTurbulence Slope corrected for heart rate and VPC count (optimized in CAST data).
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T a b l e2|P r ospective studies (or sub-studies) investigating heart rate turbulence as a post-infarction risk-predictor.
ISAR-HRT
(Barthel et al.,
2003)
REFINE
(Exner et al.,
2007)
ISAR-RISK‡‡
(Bauer et al.,
2009a)
CARISMA
(Huikuri et al.,
2009)
ISAR-Sweet‡‡
(Barthel et al.,
2011)
Number of patients 1,455 322 2,343 312 481
Inclusion criteria* MI ≤4weeks, age
≤75years
MI, LVEF <50% MI ≤4weeks, age
≤75years
MI <21days, LVEF ≤40% MI ≤4weeks, age
≤80years, diabetes
Follow-up (months) 22 47 60 24 60
Endpoint Mortality Cardiac death† Mortality VF/sustained VT on loop recorder Mortality
Endpoints reached (%) 5 9 8 8 17
Time of HRT
assessment after MI
2nd week 2nd to 4th and 10th
to 14th week
2nd week 1st and 6th week 2nd week
Treatment of acute MI 90% PCI, 6% lysis 45% PCI, 21% lysis 92% PCI, 3% lysis 14% PCI, 34 lysis 89% PCI
Mean LVEF (%) 56 47 55 31 51
Betablockers (%) 93 92 94 96 94
UNIVARIATEANALYSIS
HRT category 2 11.4 (5.7–22.8) 2.9 (1.1–7 .5)†† 7 .5 (5.3–10.7) 2.8 (1.1–7 .2)|| 6.6 (3.9–11.0)
LVEF ≤30% 7 .1 (4.2–12.1) 3.3 (1.4–7 .6) 6.1 (4.2–8.7) 1.3 (0.5–3.0)# 4.7 (2.8–7 .8)
MULTIVARIATEANALYSIS
HRT category 2 5.9 (2.9–12.2) Not speciﬁed 3.1 (2.1–4.6) Not speciﬁed 4.1 (2.3–7 .2)
LVEF ≤30% 4.5 (2.6–7 .8) Not speciﬁed 3.0 (2.0–4.4) Not speciﬁed 2.4 (1.4–4.1)
*Sinus rhythm was inclusion criterion in all studies.
†Cardiac mortality included fatal and non-fatal cardiac arrest.
||Relative risks presented for turbulence slope ≤2.5ms/RR interval.
#LVEF was dichotomized at 35%.
††HRT category ≥1 vs. 0 tested; HRT was assessed 10–14weeks after MI.
‡‡ISAR-RISK primarily tested the combination HRT category 2 and abnormal deceleration capacity (Bauer et al., 2006a).
which tested the combination of abnormal HRT and decelera-
tion capacity in diabetic post-infarction patients (Barthel et al.,
2011).
RISK PREDICTIVE POWER OF HRT IN POST-INFARCTION
PATIENTS
In all populations, abnormal HRT was a signiﬁcant and indepen-
dent predictor of adverse events yielding a relative risk of 2.8–11.4
on univariate and 3.1–5.9 on multivariate analysis.
ThesingleHRTstudiessubstantiallydifferwithrespecttostudy
design(retrospectivevs.prospective),theprimaryendpointinves-
tigated(totalmortality,cardiacmortality,andsuddendeath),time
of follow-up, time after MI when Holter recordings have been
performed, mean LVEF, and treatment of MI.
Heart rate turbulence is generally a very strong predictor in
all studies which used total mortality as primary endpoint (which
most of the studies did: MPIP, EMIAT, CAST, ISAR-HRT, ISAR-
RISK, ISAR-SWEET). HRT was also a very strong predictor in
the ATRAMI study which used a combined endpoint of car-
diac mortality and fatal and non-fatal cardiac arrest. Two studies
investigated sudden death as primary endpoint, namely the FIN-
GER study and the CARISMA study. While in the FINGER study
mode of death was determined anamnestically or with the use
of medical recordings, CARISMA had a unique study design:
all patients of the CARISMA study underwent implantation of
a loop recorder which allowed for a deﬁnite assessment of the
rhythm at time of death. While HRT was a strong predictor of
sudden death in the FINGER study, predictive power of HRT in
theCARISMAstudywassomewhatloweralthoughstillsigniﬁcant
[relative risk of abnormal TS 2.8 (95% CI 1.1–7.2), p =0.038]. It
should be noted, however, that in CARISMA only 25 endpoints
occurred during a follow-up of 2years and that only patients with
reducedLVEF(≤40%)havebeenincluded.Therefore,conclusions
drawn from the CARISMA should not be directly extrapolated
to unselected post-infarction populations with no restriction of
LVEF.
Time of HRT assessment after acute MI is an important
issue. In most HRT studies Holter recordings have been per-
formed early after MI (usually within the ﬁrst 4weeks; MPIP,
EMIAT, ATRAMI, FINGER, ISAR-HRT, ISAR-RISK, and ISAR-
SWEET). In all of these studies, HRT was a strong and signiﬁ-
cant predictor of the primary endpoint. However, also in CAST,
where risk assessment was performed later after MI, HRT was a
strong predictor of death (Hallstrom et al., 2005). In two stud-
ies,namely the REFINE and the CARISMA study,risk assessment
has been performed at two different time points. In REFINE
risk assessment has been performed between the 2nd and the
4th week as well as between the 10th and the 14th week after
MI. In CARISMA, risk assessment has been performed dur-
ing the ﬁrst week as well as during the sixth week after MI.
In both studies, risk assessment later after MI was superior
to risk assessment earlier after MI. It might therefore be con-
cluded, that HRT assessed later after MI might be a better pre-
dictor than HRT assessed early after MI. These ﬁndings are in
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agreement with the observation that autonomic dysfunction early
after MI might recover, and that patients with sustained blunted
autonomic function have the worst prognosis (Huikuri et al.,
2010).
The single HRT studies cover the whole spectrum of MI treat-
ment eras. In summary, neither acute treatment of MI (conser-
vative, lysis, PCI) nor concomitant medical treatment including
betablockers, ACE-inhibitors, or statins seem to affect risk pre-
dictive power of HRT. However, it should be noted that effective
reperfusionstrategiesforacuteMIwhichleadtoincreasedmyocar-
dialsalvagetranslateintoimprovedautonomicfunctionandbetter
HRT (Bauer et al., 2009b).
Positive predictive accuracies and sensitivities of abnormal
HRT for prediction of adverse events strongly depend on the
populations and endpoints investigated. Generally, both posi-
tive predictive accuracy and sensitivity is in the range of that
y i e l d e db yL V E F≤30%. Figure 2 exemplarily shows risk strat-
iﬁcation by HRT in the largest post-infarction study, the ISAR-
RISK study. Of the 2,343 patients studied, HRT category 2 iden-
tiﬁed a high risk group of 193 patients (8%) out of whom
56 patients died. 2,150 patients (92%) had normal (HRT cat-
egory 0 and 1) out of whom 125 patients died. Probability
of death within 5years of follow-up of patients with abnor-
mal HRT (HRT category 2) was 34%. In contrast, the 1,652
patients (71%) with completely normal HRT (HRT category
0) had a 5-year mortality of 6%. These ﬁgures translate into
a positive predictive accuracy of 34% at a sensitivity level
of 31%.
FIGURE 2 | Risk stratiﬁcation by heart rate turbulence in the ISAR-RISK
study (Bauer et al., 2009a).The number of patients of the individual
groups involved in the analyses at 0, 1, 2, 3, 4, and 5years are shown under
the graphs.The top and the bottom row corresponds to the upper and
bottom Kaplan–Meier curve respectively. For all three comparisons (HRT
category 0 vs. HRT category 1, HRT category 0 vs. HRT category 2, and
HRT category 1 vs. HRT category 2) the p-value was <0.0001. (Adapted by
permission from Bauer et al., 2009a).
INDEPENDENCY FROM AND COMBINATION WITH OTHER
RISK PREDICTORS
In all studies, predictive value of HRT was independent from that
ofotherriskpredictorstested.Theseincludeddemographicfactors
and comorbidities (age,gender,presence of diabetes mellitus,and
renalinsufﬁciency;Bartheletal.,2011),markersofelectricalinsta-
bility [arrhythmias, T-wave alternans (Exner et al., 2007), late
potentials(Baueretal.,2005),QRSduration(Baueretal.,2006b)],
markers of structural damage (e.g., LVEF), and other markers
of autonomic dysfunction (heart rate, heart rate variability, and
deceleration capacity; Bauer et al., 2006a, 2009a).
In order to enhance risk predictive power, HRT should be
combined with other risk predictors. The ISAR-RISK and the
ISAR-SWEET studies investigated the combination of abnormal
HRT (HRT category 2) with mildly abnormal deceleration capac-
ity (≤4.5ms) which is a measure of tonic autonomic activity and
bases on the processing of RR interval time series by a new math-
ematical algorithm (Bauer et al., 2006c). For this combination,
the term “severe autonomic failure (SAF)” has been introduced.
In both, ISAR-RISK and ISAR-SWEET which included 2,343 and
481 patients respectively, SAF proved to be the strongest predic-
tor of death. These ﬁndings were conﬁrmed by the results of a
recent metaanalysis which analyzed the combined populations of
the MPIP, EMIAT, and MRFAT studies (n =2,594; Bauer et al.,
2009c). Also the combination of HRT with T-wave alternans is
promising as both were independently associated with the pri-
mary endpoint in the REFINE study. However, available data do
not allow for ﬁnal conclusions.
Risk stratiﬁcation by HRT is complementary to risk stratiﬁca-
tion by LVEF. Only a small proportion of patients with abnormal
HRT (category 2) also have LVEF ≤30%. Therefore, the strength
of HRT lies in the identiﬁcation of high risk patients in the large
group of patients with preserved LVEF (>30%). Figure 3 shows
complimentary risk stratiﬁcation by HRT and LVEF in the ISAR-
RISK study (Bauer et al.,2009a). The small proportion of patients
with both, abnormal HRT and impaired LVEF (n =40; 1.7% of
the study population) had the worst prognosis. Patients with
either abnormal HRT (n =153; 6.5% of the study population)
or impaired LVEF (n =80; 3.4% of the study population) had
equally poor prognosis. In contrast, patients with normal HRT
(category 0 or 1) and LVEF >30% (n =2,070; 88.3% of the study
population) had an excellent prognosis. As mentioned above risk
stratiﬁcation by HRT can be further improved by combination
with deceleration capacity (Bauer et al., 2009a).
LIMITATIONS OF HEART RATE TURBULENCE
SeverallimitationsneedtoberecognizedwhenusingHRTasrisk-
predictor.Firstly,assessmentofHRTrequiresthepresenceofsinus
rhythm. Patients with other rhythms than sinus rhythm such as
atrial ﬁbrillation have been excluded in all HRT studies but might
be at increased risk. In the Global Utilization of Streptokinase
and Tissue plasminogen activator for Occluded coronary arteries
(GUSTO-I) trial, 10.5% of the 41,021 patients had atrial ﬁbrilla-
tion during hospitalization (Crenshaw et al.,1997). Further,most
HRT studies also excluded elderly patients (age >75years or age
>80years). It is well known from the ATRAMI study that auto-
nomic function loses some of its predictive value with increasing
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FIGURE 3 | Complimentary risk stratiﬁcation by HRT and LVEF in the ISAR-RISK study (Bauer et al., 2009a). (A) Distribution of patients with abnormal
HRT but LVEF >30% (n=153, orange area), abnormal HRT and LVEF≤30% (n=40, red area), and normal HRT but LVEF ≤30% (n=80, blue area). (B)
Corresponding 5-year mortality rates of the three groups. Abnormal HRT deﬁned as HRT category 2 (adapted by permission from Bauer et al., 2009a).
age (La Rovere et al., 1998). Similar observations have been made
for HRT in the ISAR-HRT study (Barthel et al.,2005). In contrast,
HRT was a signiﬁcant predictor for sudden death in the popu-
lation based Cardiovascular Health Study which included adults
≥65years(average73years;Steinetal.,2010).Assessmentof HRT
also requires presence of VPCs. In most studies, patients with-
out VPCs have therefore been excluded from the analysis (e.g.,
MPIP,EMIAT,ATRAMI). As shown in the ISAR-HRT study post-
infarction patients without VPCs have equally good prognosis as
patients with normal HRT (Barthel et al., 2003). Therefore, these
patientsmightbetreatedashavingnormalHRT(HRTcategory0).
HRTisusuallyassessedfromfull24-hHolterrecordings.Whether
HRT derived from shorter recordings provides similar predictive
valueneedsfurtherinvestigations.Aretrospectiveanalysisof HRT
in the Multicenter Automatic Deﬁbrillator Implantation Trial 2
thatusedonly10-minrecordingsshowedtheinappropriatenessof
veryshortrecordings(Berkowitschetal.,2004).Allpost-infarction
HRT studies included patients early after MI. A large-scale study
which investigates the prognostic value of HRT in patients with
remote infarction is still missing. This might be of substantial
importance as prophylactic ICD implantation in the acute phase
of infarction has been generally questioned by the negative results
of two randomized ICD trials (Hohnloser et al., 2004; Steinbeck
et al., 2009). It should be noted, however, that both studies, the
DINAMIT(n =674)andtheIRISstudy(n =898),usedentrycri-
teria that selected only a very small proportion of post-infarction
patients at very high risk. For instance, the IRIS study selected
898 patients out of 62,944 patients (1.4%). Conclusions drawn
from these two studies should therefore not be generalized and
extrapolated to other risk stratiﬁcation strategies.
CONCLUSION
Heartrateturbulenceiseasilyapplicablefromroutine24-hHolter
recordings. In all post-infarction studies HRT was a strong and
independent predictor of adverse events which included death of
any cause, cardiac death, and sudden death. In all post-infarction
studies, predictive value of HRT was independent from other risk
factorstested.Forpurposeofidentifyinghighriskindividualswho
might beneﬁt from prophylactic ICD implantation, HRT should
be combined with other independent predictors. Potential can-
didates include impaired LVEF, abnormal deceleration capacity,
and/or T-wave alternans. The combination of abnormal HRT and
abnormal deceleration capacity termed “SAF” has been tested in
the ISAR-RISK study and provides strong prognostic value also
in post-infarction patients with preserved LV-function. However,
only future interventional trials can ﬁnally answer the question
whether high risk patients identiﬁed by abnormal HRT beneﬁt
from prophylactic therapy.
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